Plasma N‐terminal pro BNP and cardiotrophin‐1 are elevated in aortic stenosis

Talwar, Suneel; Downie, Paul; Squire, Iain B.; Davies, Joan E.; Barnett, David; Ng, Leong L.

doi:10.1016/s1388-9842(00)00074-x

Cited by 89 publications

(49 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Increased wall stress and myocardial stretch have been shown to release BNP, which has been referred to as the only "true" ventricular hormone, in various cardiac entities 26 -28 and also in previous studies of AS. 14,16 Patients with TS AS had indeed higher gradients, whereas EF was similar in both groups. Because BNP increases with the severity of LV damage of any cause, it is not surprising that the overlap of BNP levels between PS AS and TS AS was too extensive to allow their differentiation in individual patients.…”

Section: Bnp In Low-flow Low-gradient Aortic Stenosismentioning

confidence: 81%

B-Type Natriuretic Peptide in Low-Flow, Low-Gradient Aortic Stenosis

et al. 2007

View full text Add to dashboard Cite

Background-The prognostic value of B-type natriuretic peptide (BNP) is unknown in low-flow, low-gradient aortic stenosis (AS). We sought to evaluate the relationship between AS and rest, stress hemodynamics, and clinical outcome. Methods and Results-BNP was measured in 69 patients with low-flow AS (indexed effective orifice area Ͻ0.6 cm 2 /m 2 , mean gradient Յ40 mm Hg, left ventricular ejection fraction Յ40%). All patients underwent dobutamine stress echocardiography and were classified as truly severe or pseudosevere AS by their projected effective orifice area at normal flow rate of 250 mL/s (effective orifice area Յ1.0 cm 2 or Ͼ1.0 cm 2 ). BNP was inversely related to ejection fraction at rest (Spearman correlation coefficient r s ϭϪ0.59, PϽ0.0001) and at peak stress (r s ϭϪ0.51, PϽ0.0001), effective orifice area at rest (r s ϭϪ0.50, PϽ0.0001) and at peak stress (r s ϭϪ0.46, Pϭ0.0002), and mean transvalvular flow (r s ϭϪ0.31, Pϭ0.01). BNP was directly related to valvular resistance (r s ϭ0.42, Pϭ0.0006) and wall motion score index (r s ϭ0.36, Pϭ0.004). BNP was higher in 29 patients with truly severe AS versus 40 with pseudosevere AS (median, 743 pg/mL [Q1, 471; Q3, 1356] versus 394 pg/mL [Q1, 191 to Q3, 906], Pϭ0.012). BNP was a strong predictor of outcome. In the total cohort, cumulative 1-year survival of patients with BNP Ն550 pg/mL was only 47Ϯ9% versus 97Ϯ3% with BNP Ͻ550 (PϽ0.0001). In 29 patients who underwent valve replacement, postoperative 1-year survival was also markedly lower in patients with BNP Ն550 pg/mL (53Ϯ13% versus 92Ϯ7%). Conclusions-BNP is significantly higher in truly severe than pseudosevere low-gradient AS and predicts survival of the whole cohort and in patients undergoing valve replacement.

show abstract

Section: Bnp In Low-flow Low-gradient Aortic Stenosismentioning

confidence: 81%

B-Type Natriuretic Peptide in Low-Flow, Low-Gradient Aortic Stenosis

et al. 2007

View full text Add to dashboard Cite

show abstract

“…These results suggest NT-proBNP and CT-1 could potentially be used to monitor progression of disease non-invasively. These markers may also be useful to identify the optimum time for surgery in AS 47 .…”

Section: Valvular Diseasementioning

confidence: 99%

Cardiotrophin-1 Review

Stejskal¹,

Růžička²

2008

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub

View full text Add to dashboard Cite

“…1 Our group has described that CT-1 induces cell proliferation, hypertrophy, and secretion of extracellular matrix proteins in aortic vascular smooth muscle cells (VSMCs) in vitro 2 and in vivo, 3 suggesting a role for CT-1 in arterial fibrosis and stiffness, which both are features of aging. Furthermore, elevated plasma concentrations of CT-1 have been reported in patients with a variety of diseases, including hypertension, 4 heart failure, 5 uns table angina, 6 myocardial infarction, 7 and aortic stenosis, 8 indicating that this cytokine may contribute to the development of cardiovascular pathologies associated with aging.…”

mentioning

confidence: 99%

Absence of Cardiotrophin 1 Is Associated With Decreased Age-Dependent Arterial Stiffness and Increased Longevity in Mice

et al. 2013

View full text Add to dashboard Cite

Here, we investigated whether the absence of CT-1 in mice confers protection from arterial stiffness and fibrosis with an impact on vascular senescence and overall mortality. To understand the effects of CT-1 in arterial stiffness associated with aging, we studied a cohort of senescent (29-monthold) CT-1-null mice and their wild-type (WT) littermates.Abstract-Cardiotrophin 1 (CT-1), an interleukin 6 family member, promotes fibrosis and arterial stiffness. We hypothesized that the absence of CT-1 influences arterial fibrosis and stiffness, senescence, and life span. In senescent 29-monthold mice, vascular function was analyzed by echotracking device. Arterial histomorphology, senescence, metabolic, inflammatory, and oxidative stress parameters were measured by immunohistochemistry, reverse transcription polymerase chain reaction, Western blot, and ELISA. Survival rate of wild-type and CT-1-null mice was studied. Vascular smooth muscle cells were treated with CT-1 (10 −9 mol/L) for 15 days to analyze senescence. The wall stress-incremental elastic modulus curve of old CT-1-null mice was shifted rightward as compared with wild-type mice, indicating decreased arterial stiffness. Media thickness and wall fibrosis were lower in CT-1-null mice. CT-1-null mice showed decreased levels of inflammatory, apoptotic, and senescence pathways, whereas telomere-linked proteins, DNA repair proteins, and antioxidant enzyme activities were increased. CT-1-null mice displayed a 5-month increased median longevity compared with wild-type mice. In vascular smooth muscle cells, chronic CT-1 stimulation upregulated apoptotic and senescence markers and downregulated telomere-linked proteins. The absence of CT-1 is associated with decreased arterial fibrosis, stiffness, and senescence and increased longevity in mice likely through downregulating apoptotic, senescence, and inflammatory pathways. CT-1 may be a major regulator of arterial stiffness with a major impact on the aging process. (Hypertension. 2013;61:120-129.)

show abstract

Plasma N‐terminal pro BNP and cardiotrophin‐1 are elevated in aortic stenosis

Cited by 89 publications

References 23 publications

B-Type Natriuretic Peptide in Low-Flow, Low-Gradient Aortic Stenosis

B-Type Natriuretic Peptide in Low-Flow, Low-Gradient Aortic Stenosis

Cardiotrophin-1 Review

Absence of Cardiotrophin 1 Is Associated With Decreased Age-Dependent Arterial Stiffness and Increased Longevity in Mice

Contact Info

Product

Resources

About